Patients with moderately to severely active Crohn's disease will be treated with oral CP-461
200 mg (2 x 100 mg capsules) twice-daily for 8 weeks.
The purpose of this study is to see if CP-461 improves the symptoms of Crohn's disease and/or
the patient's quality of life. Patient's safety will be monitored throughout the study.